• In late June 2026, The Estée Lauder Companies Inc. (NYSE: EL) was added to several Russell growth benchmarks and outlined a multi‑year Profit Recovery and Growth Plan expected to incur about US$1.75 billion in cumulative restructuring and related charges before tax through fiscal 2027.
• These moves signal a major reconfiguration of Estée Lauder’s cost base and go‑to‑market model, with restructuring aimed at funding reinvestment in digital capabilities, innovation, and consumer‑facing initiatives.
• We’ll now examine how these sizeable restructuring charges under the Profit Recovery and Growth Plan may reshape Estée Lauder’s existing investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

Estée Lauder Companies Investment Narrative Recap

To own Estée Lauder today, you need to believe its global brands and innovation engine can translate restructuring and digital investment into a steadier, more profitable business. The key near term catalyst remains execution on the Profit Recovery and Growth Plan, while the biggest risk is that heavy restructuring and high fixed costs weigh on margins if sales momentum disappoints. The Russell index additions do not materially change these operational risks or near term drivers.

The most relevant development here is Estée Lauder’s multi year Profit Recovery and Growth Plan, with about US$1.75 billion in expected restructuring and related charges through fiscal 2027. For investors focused on catalysts, this plan sits at the center of the margin recovery story and could influence how quickly the company can reinvest in digital channels, new products, and consumer engagement to support any future revenue and earnings improvement.

Yet beneath this recovery story, investors should be aware that prolonged weakness in travel retail and Asia could still...

Estée Lauder Companies' narrative projects $16.5 billion revenue and $1.4 billion earnings by 2029. This requires 3.6% yearly revenue growth and an earnings increase of about $1.6 billion from -$248.0 million today.

Uncover how Estée Lauder Companies' forecasts yield a $95.12 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were banking on revenue reaching about US$17.4 billion and earnings of roughly US$1.9 billion by 2029, a far brighter scenario than consensus, even as they acknowledged rising competitive and regional risks; with the new restructuring plan and index moves now in play, you may find your own view shifting somewhere between these extremes as you compare how quickly margins and growth could realistically improve.

Explore 5 other fair value estimates on Estée Lauder Companies - why the stock might be worth as much as 54% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Estée Lauder Companies research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Estée Lauder Companies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Estée Lauder Companies' overall financial health at a glance.

No Opportunity In Estée Lauder Companies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 45 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.